Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (201-210 of 404) with videos related to

Pageof 41
Sort By:
AIDS (London, England)|March 11, 2010
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruptionGregory J Dore, Vicente Soriano, Jürgen Rockstroh, et al.
Plos One|June 5, 2014
Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012Jason Grebely, Viviane Dias Lima, Brandon D L Marshall, et al.
JHEP Reports : Innovation in Hepatology|September 19, 2022
Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South WalesSyed Hassan Bin Usman Shah, Maryam Alavi, Behzad Hajarizadeh, et al.
International Journal of Epidemiology|October 16, 2003
Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001Matthew G Law, Gregory J Dore, Nicky Bath, et al.
Health Science Reports|April 10, 2020
Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trialJason Grebely, Phillip Read, Evan B Cunningham, et al.
The Journal of Infectious Diseases|March 30, 2012
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study designPeter Vickerman, Jason Grebely, Gregory J Dore, et al.
Virology Journal|February 26, 2016
Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infectionBehzad Hajarizadeh, François Mj Lamoury, Jordan J Feld, et al.
Journal of Hepatology|November 28, 2012
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infectionMatthew T Kitson, Gregory J Dore, Jacob George, et al.
JHEP Reports : Innovation in Hepatology|March 14, 2024
Corrigendum to "Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales" [JHEP Reports 4 (2022)]Syed Hassan Bin Usman Shah, Maryam Alavi, Behzad Hajarizadeh, et al.
Journal of Viral Hepatitis|November 8, 2023
Incidence of hepatitis C virus infection in the prison setting: The SToP-C studyBehzad Hajarizadeh, Joanne M Carson, Marianne Byrne, et al.
Pageof 41

Showing results (201-210 of 404) with videos related to

Sort By:
Pageof 41
AIDS (London, England)|March 11, 2010
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruptionGregory J Dore, Vicente Soriano, Jürgen Rockstroh, et al.
Plos One|June 5, 2014
Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012Jason Grebely, Viviane Dias Lima, Brandon D L Marshall, et al.
JHEP Reports : Innovation in Hepatology|September 19, 2022
Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South WalesSyed Hassan Bin Usman Shah, Maryam Alavi, Behzad Hajarizadeh, et al.
International Journal of Epidemiology|October 16, 2003
Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001Matthew G Law, Gregory J Dore, Nicky Bath, et al.
Health Science Reports|April 10, 2020
Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trialJason Grebely, Phillip Read, Evan B Cunningham, et al.
The Journal of Infectious Diseases|March 30, 2012
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study designPeter Vickerman, Jason Grebely, Gregory J Dore, et al.
Virology Journal|February 26, 2016
Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infectionBehzad Hajarizadeh, François Mj Lamoury, Jordan J Feld, et al.
Journal of Hepatology|November 28, 2012
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infectionMatthew T Kitson, Gregory J Dore, Jacob George, et al.
JHEP Reports : Innovation in Hepatology|March 14, 2024
Corrigendum to "Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales" [JHEP Reports 4 (2022)]Syed Hassan Bin Usman Shah, Maryam Alavi, Behzad Hajarizadeh, et al.
Journal of Viral Hepatitis|November 8, 2023
Incidence of hepatitis C virus infection in the prison setting: The SToP-C studyBehzad Hajarizadeh, Joanne M Carson, Marianne Byrne, et al.
Pageof 41